Scinai Immunotherapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Scinai Immunotherapeutics has a total shareholder equity of $10.0M and total debt of $280.0K, which brings its debt-to-equity ratio to 2.8%. Its total assets and total liabilities are $12.3M and $2.3M respectively.
Key information
2.8%
Debt to equity ratio
US$280.00k
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.03m |
| Equity | US$10.00m |
| Total liabilities | US$2.26m |
| Total assets | US$12.26m |
Recent financial health updates
Recent updates
Why Scinai Immunotherapeutics' (NASDAQ:SCNI) Healthy Earnings Aren’t As Good As They Seem
Nov 29
Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt
Nov 10Bionvax Pharmaceuticals GAAP EPS of -NIS0.02
Aug 25BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan
Aug 10We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt
Mar 31BiondVax Pharmaceuticals under pressure on pricing $12.1M ADSs follow-on offering
Jan 29Financial Position Analysis
Short Term Liabilities: SCNI's short term assets ($1.6M) exceed its short term liabilities ($1.4M).
Long Term Liabilities: SCNI's short term assets ($1.6M) exceed its long term liabilities ($866.0K).
Debt to Equity History and Analysis
Debt Level: SCNI has more cash than its total debt.
Reducing Debt: SCNI had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: SCNI's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if SCNI's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 17:36 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Scinai Immunotherapeutics Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| David Bautz | Zacks Investment Research Inc. |
| David Bautz | Zacks Small-Cap Research |